Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Protein Manufacturing
Overview

 

Catalog Products
Online Store
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events

In the News

Contact Us

ImmunoPrecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”) financing in the principal amount of $250,000.  In total, ImmunoPrecise issued $4,252,000 of Debentures under the entire financing.

The Debentures are unsecured, bear interest at a rate of 10% per annum, payable semi-annually, and be due eighteen months from the date of issue.  Under the debenture financing, a holder of a Debenture received 37,500 detachable share purchase warrants (the “Warrants”) for every $25,000 of Debentures subscribed for by the holder.  The Warrants are exercisable at $0.70 per share for a period of four years from the date of issue

The proceeds of the Offering were used to satisfy the closing cash payment to acquire ModiQuest and Immulease.  Under the Offering, ImmunoPrecise paid the following finder’s fees: $10,000 in cash, 573,980 in shares of ImmunoPrecise and 415,942 Warrants.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care and in association with U-Protein Express B.V. its subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands.

The services offered to customers include the development of wild-type and humanized mouse and rat monoclonal antibodies and recombinant rabbit monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically-based assays, recombinant protein manufacturing, and advanced solutions to challenges faced by clients in antibody-related research and development.  In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

ImmunoPrecise employs a highly experienced group of R&D scientists.  Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.

For further information please contact:

ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO
3204-4464 Markham Street.
Victoria, BC V8Z 7X8
www.ipatherapeutics.com

For investor relations please contact:

Frederick Chabot
Phone: 1-438-863-7071
Email: frederick@contactfinancial.com
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5

 

Forward Looking Information

 

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. ImmunoPrecise uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties.  Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for ModiQuest being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Register for IPA Updates

By clicking submit below, you agree that IPA may store and process your personal information to send you email updates. You can find further information in our Privacy Policy.

Connect with IPA